{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:48:46Z","timestamp":1757616526988,"version":"3.44.0"},"reference-count":5,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Fam Plann Reprod Health Care"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1136\/jfprhc-2012-100344","type":"journal-article","created":{"date-parts":[[2012,7,11]],"date-time":"2012-07-11T10:58:08Z","timestamp":1342004288000},"page":"205.2-206","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Is it ethical to use drospirenone-containing combined oral contraceptives?"],"prefix":"10.1136","volume":"38","author":[{"given":"Rudiger","family":"Pittrof","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2012,7,11]]},"reference":[{"key":"2025090512383139000_38.3.205-b.1","doi-asserted-by":"publisher","DOI":"10.1136\/jfprhc-2011-100260"},{"key":"2025090512383139000_38.3.205-b.2","unstructured":"Ouellet-Hellstrom R Graham DJ Saffa JA . Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints (CHC-CVD Final Report 111022v2). http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM277384.pdf [accessed 12 January 2012]."},{"key":"2025090512383139000_38.3.205-b.3","unstructured":"Beuachamp TL Childress JF . Principles of Biomedical Ethics (6th edn). Oxford, UK: Oxford University Press, 2009."},{"key":"2025090512383139000_38.3.205-b.4","doi-asserted-by":"crossref","unstructured":"Lawrie TA Helmerhorst FM Maitra NK . Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Database Syst Rev 2011;5:CD004861.","DOI":"10.1002\/14651858.CD004861.pub2"},{"key":"2025090512383139000_38.3.205-b.5","unstructured":"Mechcatie E . FDA Panel Reviews VTE Risk Drospirenone-Containing OCs Family Practice News. http:\/\/www.familypracticenews.com\/news\/more-top-news\/single-view\/fda-panel-reviews-vte-risk-drospirenone-containing-ocs\/9ce4d7fab5.html [accessed 12 January 2012]."}],"container-title":["Journal of Family Planning and Reproductive Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jfprhc-2012-100344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T19:38:37Z","timestamp":1757101117000},"score":1,"resource":{"primary":{"URL":"https:\/\/jfprhc.bmj.com\/lookup\/doi\/10.1136\/jfprhc-2012-100344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":5,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,7,11]]},"published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1136\/jfprhc-2012-100344"],"URL":"https:\/\/doi.org\/10.1136\/jfprhc-2012-100344","relation":{},"ISSN":["1471-1893","2045-2098"],"issn-type":[{"type":"print","value":"1471-1893"},{"type":"electronic","value":"2045-2098"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}